UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

Presentations
Comprehensive mutation analysis in NRG Oncology/RTOG 9813:
A phase III trial of RT + TMZ vs RT + nu for anaplastic astrocytoma
and mixed anaplastic oligoastrocytoma (Astrocytoma Dominant).
Authors*: Erica Hlavin Bell, Joseph P McElroy, Jessica Fleming, Cynthia Dawn Timmers, Arup R Chakraborty,
Andrea L Salavaggione, Susan Marina Chang, Kenneth D. Aldape, David Brachman, Helen Alice Shih,
Peixin Zhang, Minesh P. Mehta, Arnab Chakravarti
Abstract #: 2016
Presentation Date/Time: Saturday, June 4: 1:00 - 4:30 PM
Location: Hall A, Poster Board # 205
Session: Central Nervous System Tumors
Citation: J Clin Oncol 34, 2016 (suppl; abstr 2016)
Chang Research Interests: My research interest is in the development of novel therapies for patients with brain
tumors, as well as the assessment of novel imaging biomarkers in the management of patients. My research
seeks to integrate advances in physiologic and metabolic imaging with tissue biomarkers in order to optimize
the management of patients with glioblastoma (GBM). My clinical research evaluates a wide spectrum of
therapeutic interventions that span chemotherapy, targeted agents, immunotherapy and convection enhanced
delivery of novel agents. I am the site PI of an NIH-funded adult brain tumor consortium and am a member
of the Brain Malignancy Steering Committee and the Developmental Therapeutics Study Section at the NIH. I
am the program leader for the Neuro-Oncology Program at the HDFCCC. I am the clinical co-PI for the UCSF
Brain Tumor SPORE and a co-Leader of a SPORE Project evaluating the role of physiologic imaging in the
determination of malignant progression of low-grade glioma.
http://cancer.ucsf.edu/people/profiles/chang_susan.3565
*UCSF authors in bold
18